<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536092</url>
  </required_header>
  <id_info>
    <org_study_id>C-15-HR-03</org_study_id>
    <nct_id>NCT02536092</nct_id>
  </id_info>
  <brief_title>A Prospective Multi-Center Study of a Novel Dual-Wavelength Laser for Hair Removal</brief_title>
  <official_title>A Prospective Multi-Center Study of a Novel Dual-Wavelength Laser for Hair Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutera Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutera Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of the Cutera excel HR dual wavelength 755nm Alexandrite
      and 1064nm Nd:YAG laser for hair removal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center prospective, open-label, uncontrolled multi-center study of up to 50
      male or female subjects, age 18 to 65 years, who desire laser hair removal. Subjects will
      receive 6 hair removal treatments, spaced 8 weeks apart, and will be followed at 12 weeks
      post-final treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor terminated study
  </why_stopped>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physician's Global Assessment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of hair reduction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse device effects</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessment of ADEs immediately following each laser treatment and at the final follow-up visit</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hypertrichosis</condition>
  <arm_group>
    <arm_group_label>755nm and 1064nm Nd:YAG laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>755nm and 1064nm Nd:YAG laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>755nm and 1064nm Nd:YAG laser</intervention_name>
    <description>Dual wavelength 755nm and 1064nm Nd:YAG laser</description>
    <arm_group_label>755nm and 1064nm Nd:YAG laser</arm_group_label>
    <other_name>Excel HR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or Male, 18 to 65 years of age (inclusive).

          -  Fitzpatrick Skin Type I - VI (Appendix 3).

          -  Subject has black or dark brown unwanted hair.

          -  Subject must be able to read, understand and sign the Informed Consent Form.

          -  Must be willing and able to adhere to the treatment and follow-up schedule and
             post-treatment care instructions.

          -  Willing to refrain from shaving the treatment area for 5 days prior to each study
             visit.

          -  Willing to have digital photographs taken of the treatment area and agree to use of
             photographs for presentation, educational or marketing purposes.

          -  Must agree not to use hair removal products, such as topical chemical depilatories, or
             undergo any other hair removal procedure during the study, such as other laser and
             light therapies or waxing.

          -  Willing to refrain from excess sun exposure and willing to wear sunscreen on the
             treatment area during the study (including the follow-up period).

          -  Be in good health, as determined by the Investigator.

          -  Post-menopausal or surgically sterilized, or using a medically acceptable form of
             birth control at least 3 months prior to enrollment and during the entire course of
             the study

        Exclusion Criteria:

          -  Participation in a clinical trial of another device or drug within 6 months prior to
             enrollment or during the study.

          -  Had any type of professional hair removal procedure, such as laser, light-based, RF or
             electrolysis, in the treatment area within 12 months of study participation.

          -  Had other epilation treatment, such as waxing or mechanical epilator, in the treatment
             area within 6 months of study participation.

          -  Subject shows signs of actinic bronzing or recent tanning in the treatment area, and
             unable/unlikely to refrain from tanning during the study

          -  History of malignant tumors in the target area.

          -  Pregnant and/or breastfeeding.

          -  Having an infection, dermatitis or a rash in the treatment area.

          -  Significant concurrent illness, such as diabetes mellitus or cardiovascular disease,
             e.g., uncontrolled hypertension.

          -  Suffering from coagulation disorders or taking prescription anticoagulation
             medications.

          -  History of keloid scarring, hypertrophic scarring or of abnormal wound healing.

          -  Currently using immunosuppressive medications or history of immunosuppression/immune
             deficiency disorder, such as psoriasis, eczema, vitiligo, systemic lupus erythematosus
             or scleroderma.

          -  History of seizure disorders due to light.

          -  Any use of medication that is known to increase sensitivity to light according to
             Investigator's discretion.

          -  History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes
             zoster (shingles) in the treatment area, unless treatment is conducted following a
             prophylactic regimen

          -  History of radiation to the treatment area or undergoing systemic chemotherapy for the
             treatment of cancer.

          -  History of pigmentary disorders, particularly tendency for hyper- or
             hypo-pigmentation.

          -  Systemic use of corticosteroid or isotretinoin within 6 months of study participation.

          -  Anytime in life, having have used gold therapy (gold salts) for disorders such as
             rheumatologic disease or lupus.

          -  Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning
             during the study.

          -  Current smoker or history of smoking within 6 months of study participation.

          -  As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lezara Laser &amp; Vein Care</name>
      <address>
        <city>Squamish</city>
        <state>British Columbia</state>
        <zip>V5B0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Body Bar Laser Clinic/Academy</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V4P1B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrichosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study terminated</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

